Tag: addyi

From The Hastings Center Report: "Addyi, a drug that made a splash when it was approved in the summer of 2015 as the first...

From Bloomberg: "The counterattack against the drug has been furious, and in many instances led by women. These forces contend that one woman’s sexual abnormal...

From The Hastings Center: Three years ago, a pharmaceutical company created and funded a feminist group called Even the Score to campaign for FDA approval of...

“It’s the biggest secret in medicine,” said F. Perry Wilson, a researcher and physician at Yale University School of Medicine. “For the vast majority of...

From STAT: It “looks like the FDA is using this guidance to keep another company from trying to get a female sexual desire drug approved...

The drug watch blog Evidencer.org takes on Flibanserin (Addyi) the first drug claiming “to enhance women’s sexual drive…” Article →

Despite concerns about the risk to benefit ratio, the FDA approved flibanserin (Addyi) to treat low female sexual desire in August. In a new...

“A STAT examination of hundreds of social media accounts maintained by health-care professionals finds that while they often tweet medical advice, they almost never disclose potential conflicts of...

Pharmaguy covers a study published in JAMA this month which found that Addyi, the new drug approved by the FDA to treat low sexual...

“The Food and Drug Administration’s approval of pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex,” Maya Dusenbery writes in the Pacific Standard. Is “female Viagra” a feminist victory or a product of clever faux-feminist marketing by Big Pharma?

“The National Women’s Health Network launched the 'Pass on the Pink Pill – Or Pass Out' campaign, to warn women of the marginal benefits...

Ed Silverman reports that only 80 prescriptions for Addyi, or Flibanserin, were filled in the drugs’ first two weeks on the market. Article →

Despite concerns about the drug’s necessity, effectiveness, and side-effects, Flibanserin (Addyi) has come to market as the first drug designed to increase sexual desire in women